ArticleMedicina oral, patologia oral y cirugia bucal2025
Efficacy of leukocyte- and platelet-rich fibrin in the treatment and prevention of medication-related osteonecrosis of the jaw: a prospective study.
Article in Medicina oral, patologia oral y cirugia bucal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The tooth transformer® revolution: autologous dentin biomaterials and platelet concentrates in oral regeneration. A parallel narrative systematic review.Frontiers in dental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedication-related osteonecrosis of the jaws (MRONJ) is a serious condition associated with bone modifying agents (BMAs) intake, leading to impaired bone healing and increased morbidity. Despite various therapeutic approaches, an optimal treatment strategy remains elusive. Leukocyte- and Platelet- Rich fibrin (L-PRF) has emerged as a promising autologous biomaterial due to its regenerative properties. This study aimed to evaluate the efficacy of L-PRF in the treatment and prevention of MRONJ. MATERIAL AND
methodsA prospective cohort study was conducted, including a total of 30 patients diagnosed with MRONJ (stage I or II) or at risk of developing it (non-MRONJ). Patient underwent standardized treatment involving surgical debridement followed by L-PRF application. Clinical and demographic data were collected, and healing outcomes were assessed at multiple follow-up intervals (7 days, 14 days, 1 month, 3 months and 6 months). Statistical analyses, including Kaplan-Meier survival estimates, were performed to evaluate treatment effectiveness.
resultsThe study demonstrated an overall healing of 90%, with a complete recovery in 82.4% of confirmed MRONJ cases and 100% of at-risk patients. L-PRF exhibited good clinical outcomes, including reduced inflammation and pain, accelerated epithelialization, and improved tissue regeneration. The median healing time was estimated at 33.41 days for MRONJ patients and 11.00 for non-MRONJ. No significant differences in healing rates were observed based on age, sex, or systemic conditions.
conclusionsL-PRF represents a promising adjunct in MRONJ management, improving healing outcomes and postoperative recovery. Its autologous nature and growth factor release enhance bone regeneration, suggesting its potential as both a therapeutic and preventive strategy. Further larger-scale clinical trials are needed to standardize protocols and validate long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.